PCORI Funds Head-To-Head Drug Trial For Non-diabetic Neuropathy
This article was originally published in The Pink Sheet Daily
Executive Summary
Four drugs will be entered into an adaptive trial to find out which one is most effective and has the fewest side effects for treating cryptogenic sensory polyneuropathy, a designation for neuropathy for which no cause is found.